drugset / Trial / NCT00982345

Brain Imaging of Quetiapine Response in Anxious Depression

NCT00982345

Phase 4 Completed 20 enrolled Indiana University AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out what parts of the brain have increased or decreased connectivity when people are depressed and how Seroquel extended release (XR) changes this connectivity in depressed patients. The genetic samples collected are to look at variation in a gene (serotonin transporter gene), which affects the functioning of the chemical serotonin in the brain.

Timeline

Start
2009-03
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 400 mg